TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04817501

Intervention type: OTHER
Intervention: Taking 5 ml of venous blood at different time intervals

Intervention type: OTHER
Intervention: Taking 5 ml of venous blood at different time intervals

Intervention type: OTHER
Intervention: Taking 5 ml of venous blood at different time intervals

Intervention type: OTHER
Intervention: Taking 5 ml of venous blood at different time intervals

Intervention type: OTHER
Intervention: Taking 5 ml of venous blood at different time intervals

Intervention type: OTHER
Intervention: Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any

Intervention type: OTHER
Intervention: Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any

Intervention type: OTHER
Intervention: Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any

Intervention type: OTHER
Intervention: Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any
Study: NCT05246332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Grounding
Description: The investigators used a grounding wire and a sham grounding wire to create grounding and sham-grounding groups. Participants sat on a chair barefoot in contact with the grounding mat for 30 minutes. The participants were blinded to the grounding because they did not know which one had a grounding effect according to the exterior of the mat.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Grounding
Description: The investigators used a grounding wire and a sham grounding wire to create grounding and sham-grounding groups. Participants sat on a chair barefoot in contact with the grounding mat for 30 minutes. The participants were blinded to the grounding because they did not know which one had a grounding effect according to the exterior of the mat.
Study: NCT03591081

Intervention type: OTHER
Group type: OTHER
Intervention: Intellin smart phone application
Description: This feasibility study will explore if creating an electronic platform Intellin smart phone application can promote and support timely self-referral for individuals with a recently healed DFU. It will explore the software applications acceptance and ease of use for patients.
Study: NCT00784797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mifepristone and misopristol
Description: 200 mg mifepristone and after 48 hours vaginal misopristol 800 mgr followed by oral misopristol 400 mgr every 3 hours for maxamum 5 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mifepristone and oxytocin
Description: 200 mg mifepristone followed 48 hours with high dose oxytocin drip (9 unit per hour)
Study: NCT00112905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT02583334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (30# acupuncture needle)
Description: Acupuncture will be applied by inserting acupuncture needle into acupoints (LI4, LI11, LR3, ST36, SP6, GB34)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Streitberger device will be applied by onto acupoints (LI4, LI11, LR3, ST36, SP6, GB34). The device will not really insert the blunt needle into skin but let the participants feel like real acupuncture (Lancet 1998; 352: 364-365.).
Study: NCT03336255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: South Asian Healthy Lifestyle Initiative (SAHELI)
Description: Culturally tailored lifestyle intervention for South Asians.
Study: NCT04391959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZR-MD-001 Active
Description: AZR-MD-001 is an active ophthalmic ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZR-MD-001 Vehicle
Description: AZR-MD-001 is a vehicle ophthalmic ointment
Study: NCT01231997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: 100mg Single Oral Dose of

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: 100mg Single Oral Dose of

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: 100mg Single Oral Dose of

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: 100mg Single Oral Dose of
Study: NCT01937455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1-PG9DP
Description: 4x10\^12 vg administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1-PG9DP
Description: 4x10\^13 vg administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1-PG9DP
Description: 8x10\^13 vg administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1-PG9DP
Description: 1.2x10\^14 vg administered intramuscularly
Study: NCT03351777

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PR022
Description: Topical Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR022
Description: Topical Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR022
Description: Topical Gel
Study: NCT03194984

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrogen peroxide 35%
Description: The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrogen peroxide 35%
Description: The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrogen peroxide 38%
Description: The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrogen peroxide 38%
Description: The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.
Study: NCT03412773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg once every 3 weeks (Q3W), intravenous dosing (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400 mg twice daily (BID), oral dosing
Study: NCT03705793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Irrigation
Description: Participants will undergo an 8-week treatment course that includes nasal saline irrigation with mometasone powder and placebo nasal spray.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Nasal Spray
Description: Participants will undergo an 8-week treatment course that includes placebo saline irrigation with mometasone nasal spray.
Study: NCT02641509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBI during polypectomy
Description: NBI to perform the polipectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: no NBI during polypectomy
Description: no NBI to perform the polypectomy
Study: NCT02672085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP infiltraiton
Description: Two time with 1 month interval, PRP will be extracted from own blood's patients with Regenlab® extraction kit, and injected into supraspinatus interstitial lesion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needling
Description: Two time with 1 month interval, saline water will be injected into supraspinatus interstitial lesion.
Study: NCT06133660

Intervention type: PROCEDURE
Intervention: pars plana vitrectomy
Description: pars plana vitrectomy and Silicone oil removal to distinguish subjects

Intervention type: PROCEDURE
Intervention: pars plana vitrectomy
Description: pars plana vitrectomy and Silicone oil removal to distinguish subjects
Study: NCT01869647

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ultra low dose CT scan
Description: Ultra low dose CT scan
Study: NCT01221935

Intervention type: OTHER
Intervention: SNRI or SSRI first-line treatment charts
Description: 800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs) (excluding Pristiq) within the past 6 months as a first-line treatment.

Intervention type: OTHER
Intervention: SNRI or SSRI second-line treatment charts
Description: 800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)(excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).
Study: NCT02881567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: High yield formulation
Study: NCT01869647

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Regular CT or Low Dose CT scan
Description: Regular CT or Low Dose CT scan

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: No imaging
Description: No imaging
Study: NCT01390909

Intervention type: DRUG
Intervention: Anti-epileptic drug (AED)
Description: Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.

Intervention type: DRUG
Intervention: Anti-epileptic drug (AED)
Description: Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.
Study: NCT02456714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Study: NCT00610090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UniFit AAA Stent Graft
Description: Endovascular repair of Abdominal Aortic Aneurysms
Study: NCT01696097

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DASH diet counseling
Description: Comparison of protein source (chicken and fish vs. pork) as part of DASH diet on blood pressure regulation and blood lipids.
Study: NCT03447678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: humanized antibody used in cancer immunotherapy
Study: NCT03814239

Intervention type: OTHER
Intervention: protocol
Description: In patients of Group Protocol , basal crystalloid infusion was started at 4 ml/kg/h right after general anesthesia induction and intubation. ClearSight System (Edwards Lifesciences Cop, Irvine, CA, USA) was used to measure stroke volume variation and cardiac output, continuously and noninvasively through finger- cuffed technology. If SVV was \>15% rapid crystalloid bolus of 10ml/kg or 4ml/kg colloid bolus were administered until it reached a value of ≤15%. After two consecutive fluid boluses SVV remained \>15%, administration of noradrenaline infusion was considered.
Study: NCT00716248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bucillamine
Description: bucillamine 100 mg, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: methotrexate 6 mg or more per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: methotrexate 6 mg or more per week
Study: NCT02562365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide, Cyclophosphamide, Carboplatin
Description: CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5)+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
Study: NCT01390909

Intervention type: DRUG
Intervention: Anti-epileptic drug (AED)
Description: Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.

Intervention type: DRUG
Intervention: Anti-epileptic drug (AED)
Description: Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.

Intervention type: DRUG
Intervention: Anti-epileptic drug (AED)
Description: Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.

Intervention type: DRUG
Intervention: Anti-epileptic drug (AED)
Description: Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.
Study: NCT03312517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant 10 mg
Description: Subject will receive suvorexant 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant 20 mg
Description: Subject will receive suvorexant 20mg

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo oral capsule
Description: Subject will receive placebo.
Study: NCT02624557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Subjects will receive a single dose of 300 mg alpelisib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Subjects will receive a single dose of 300 mg alpelisib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Subjects will receive a single dose of 300 mg alpelisib.
Study: NCT03737578

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delivery of a connected pedometer / accelerometer
Description: Delivery of a connected pedometer / accelerometer that the patient will be asked to wear at least 7 consecutive days / month.~Quality of life and leg restless syndrome questionnaires (auto questionnaire) completed by the patients every 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delivery of a connected pedometer / accelerometer
Description: Delivery of a connected pedometer / accelerometer that the patient will be asked to wear at least 7 consecutive days / month.~Quality of life and leg restless syndrome questionnaires (auto questionnaire) completed by the patients every 3 months
Study: NCT01871090

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unpaired remote monitoring transmitter
Description: Unpaired remote monitoring transmitter
Study: NCT04507087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Documentary
Description: A 20-minute documentary about the health, environmental, and animal welfare consequences of eating meat and animal products

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: A 20-minute unrelated video (a motivational talk entitled Listening to shame)
Study: NCT03346408

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: patient (self-questionnaire) and algologist physician (questionnaire)
Study: NCT06101576

Intervention type: PROCEDURE
Intervention: TUIP
Description: Patient who underwent transurethral incision of the prostate (TUIP) using electrical current or laser beam.

Intervention type: PROCEDURE
Intervention: TURP
Description: Patient who underwent transurethral resection of the prostate (TURP) using momopolar or bipolar current.

Intervention type: PROCEDURE
Intervention: Prostate Vaporization
Description: Patient who underwent vaporization of the prostate using plasma or laser energy (GreenLight PVP and Thulium vaporization of the prostate).

Intervention type: PROCEDURE
Intervention: AEEP
Description: Patient who underwent anatomical endoscopic enucleation of the prostate (AEEP) using Holmium, Thulium or GreenLight laser or bipolar current.
Study: NCT01516515

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SR-T100 with 2.3% of SM
Description: 2.3% of SM in Solanum undatum plant extract
Study: NCT02828072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SKY therapy
Description: slow breathing

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: usual drug therapy
Study: NCT03509220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBK-1701TC
Description: The subject will receive PBK-1701TC for colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral preparation
Description: The subject will receive the standard oral preparation for colonoscopy
Study: NCT00149318

Intervention type: OTHER
Intervention: Biochemical analyses.
Description: Biochemical analyses.
Study: NCT05813808

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultra-low-dose computed tomography
Description: 7 ultra-low-dose computed tomography imaging
Study: NCT01198613

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Ragweed
Description: Intradermal injection 1 x8 administrations 2 weeks apart
Study: NCT03269344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin is an anticonvulsant and has been used to manage neuropathic pain and is FDA-approved for the treatment of post-herpetic neuralgia and partial onset seizures

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo
Study: NCT00860158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib 100 mg administered once daily per oral route for 28 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate (LHRH Analogue)
Description: Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.
Study: NCT00002944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given PO and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given PO and IV
Study: NCT02174718

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal D Patch

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Transdermal D Patch

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral vitamin D3
Study: NCT01198613

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Ragweed
Description: Intradermal injection 1 x8 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Ragweed
Description: Intradermal injection 1 x8 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Ragweed
Description: Intradermal injection 1 x8 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection, 1x8 administrations 2 weeks apart
Study: NCT02174718

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo patch

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo patch

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral placebo
Study: NCT01613326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 50 μg inhalation capsules once a day, delivered via SDDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 μg once a day delivered via HandiHaler® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to tiotropium
Description: Placebo to tiotropium 18 μg o.d. once a day delivered via HandiHaler® device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to NVA237
Description: Placebo to NVA237 50 μg once a day delivered via SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol/albuterol
Description: salbutamol/albuterol given as a rescue medication via inhaler when needed
Study: NCT03479632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic walking program
Description: Participants will make 24 visits over an 8 week period, having 3 sessions per week. Each session will last about one hour.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: Participants will receive standard care they normally would after a stroke.
Study: NCT03980938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neflamapimod
Description: 40 mg neflamapimod capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: neflamapimod
Description: 40 mg neflamapimod capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsule
Study: NCT02750358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: assessment
Study: NCT03798886

Intervention type: OTHER
Intervention: natural cycle
Description: When follicle is ready for ovulation, we will use this injection by intra-dermal route

Intervention type: OTHER
Intervention: natural cycle
Description: When follicle is ready for ovulation, we will use this injection by intra-dermal route
Study: NCT02150538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy pacemaker
Description: biventricular stimulation with cardiac resynchronization therapy pacemaker (crt-p)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual chamber pacemaker
Description: right ventricular stimulation with dual chamber pacemaker
Study: NCT01758536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huatuo Zaizao Pills
Description: A tens of herbs botanical drug product 12 gram (g) in 72 mini pills formulation. It is to be used as 12 g each time, twice daily.